Literature DB >> 33164861

Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.

Stergios A Polyzos1, Eun Seok Kang2, Emmanuel A Tsochatzis3, Stergios Kechagias4, Mattias Ekstedt4, Stavra Xanthakos5, Amedeo Lonardo6, Alessandro Mantovani7, Herbert Tilg8, Isabelle Côté9, Aldo Grefhorst10, Michael W Greene11, David Araujo-Vilar12, Anna Alisi13, Felipe Casanueva14, Christos S Mantzoros15.   

Abstract

Entities:  

Keywords:  Fibrosis; Insulin resistance; Metabolic associated fatty liver disease; Nomenclature; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh：

Year:  2020        PMID： 33164861     DOI： 10.1016/j.metabol.2020.154413

Source DB:  PubMed          Journal:  Metabolism        ISSN： 0026-0495            Impact factor:   8.694


× No keyword cloud information.
  11 in total

Review 1.  Intra-pancreatic fat deposition: bringing hidden fat to the fore.

Authors:  Maxim S Petrov; Roy Taylor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-08       Impact factor: 46.802

Review 2.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

Review 3.  Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.

Authors:  Stergios A Polyzos; Dimitrios G Goulis; Olga Giouleme; Georgios S Germanidis; Antonis Goulas
Journal:  Curr Obes Rep       Date:  2022-05-02

Review 4.  MAFLD and CKD: An Updated Narrative Review.

Authors:  Alessandro Mantovani; Rosa Lombardi; Filippo Cattazzo; Chiara Zusi; Davide Cappelli; Andrea Dalbeni
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 5.  Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment.

Authors:  Bo Zhu; Siu-Lung Chan; Jack Li; Kathryn Li; Hao Wu; Kui Cui; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2021-09-07

6.  Cholesterol-induced leucine aminopeptidase 3 (LAP3) upregulation inhibits cell autophagy in pathogenesis of NAFLD.

Authors:  Lina Feng; Yanping Chen; Ke Xu; Yingchao Li; Farooq Riaz; Kaikai Lu; Qian Chen; Xiaojuan Du; Litao Wu; Dan Cao; Chunyan Li; Shemin Lu; Dongmin Li
Journal:  Aging (Albany NY)       Date:  2022-04-11       Impact factor: 5.682

Review 7.  Treatments for NAFLD: State of Art.

Authors:  Alessandro Mantovani; Andrea Dalbeni
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

Review 8.  Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.

Authors:  Clarissa Berardo; Laura Giuseppina Di Pasqua; Marta Cagna; Plinio Richelmi; Mariapia Vairetti; Andrea Ferrigno
Journal:  Int J Mol Sci       Date:  2020-12-17       Impact factor: 5.923

Review 9.  Targeting Wnt/β-Catenin Pathways in Primary Liver Tumours: From Microenvironment Signaling to Therapeutic Agents.

Authors:  Federico Selvaggi; Teresa Catalano; Roberto Cotellese; Gitana Maria Aceto
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

10.  Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.

Authors:  Nikolaos Perakakis; Pavlina Chrysafi; Michael Feigh; Sanne Skovgard Veidal; Christos S Mantzoros
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.